Ísrael - enska - Ministry of Health

astrazeneca (israel) ltd - quetiapine fumarate - tablets extended release - quetiapine fumarate 400 mg - quetiapine - seroquel xr is indicated for the treatment of schizophrenia .seroquel xr is effective in preventing relapse in stable schizophrenic patients who have been maintained on seroquel xr. seroquel xr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder.treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.seroquel xr is indicated for the treatment of major depressive episodes in bipolar disorder. seroquel xr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment as monotherapy or in combination with lithium or sodium valproate. seroquel xr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 pharmacodynamic properties). prior to initiating treatment, clinicians should consider the safety profile of seroquel xr (see section 4.4 special warnings and precautions for use).

Ísrael - enska - Ministry of Health

astrazeneca (israel) ltd - selumetinib as hyd-sulfate - hard capsule - selumetinib as hyd-sulfate 10 mg - selumetinib - koselugo is indicated for the treatment of pediatric patients 2 years of age and older withneurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn).

Ísrael - enska - Ministry of Health

astrazeneca (israel) ltd - selumetinib as hyd-sulfate - hard capsule - selumetinib as hyd-sulfate 25 mg - selumetinib - koselugo is indicated for the treatment of pediatric patients 2 years of age and older withneurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn).

Ísrael - enska - Ministry of Health

astrazeneca (israel) ltd - budesonide; formoterol fumarate dihydrate; glycopyrronium - suspension for inhalation - formoterol fumarate dihydrate 5 mcg; glycopyrronium 7.2 mcg; budesonide 160 mcg - budesonide - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist

Ísrael - enska - Ministry of Health

astrazeneca (israel) ltd - tezepelumab - solution for injection - tezepelumab 110 mg/ml - tezepelumab - tezspire is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

Ísrael - enska - Ministry of Health

astrazeneca (israel) ltd - aclidinium bromide - powder for inhalation - aclidinium bromide 0.4 mg - aclidinium bromide - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)

Ísrael - enska - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapy :faslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy.combination therapy with palbociclib: faslodex is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy

Ísrael - enska - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapy :faslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy.combination therapy with palbociclib: faslodex is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy

Ísrael - enska - Ministry of Health

astra zeneca (israel) ltd - zolmitriptan - tablets soluble in mouth - zolmitriptan 2.5 mg - zolmitriptan - zolmitriptan - acute treatment of migraine with or without aura.

Ísrael - enska - Ministry of Health

astra zeneca (israel) ltd - gefitinib - film coated tablets - gefitinib 250 mg - gefitinib - iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating mutations of egfr-tk.